(Q38584379)

4 September 2017

title

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance (English)

1 reference

4 September 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Frank L. Heppner

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

M Dietel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

K Jöhrens

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M V Laffert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

H Bläker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

B M Pfitzner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A Lehmann

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S Darb-Esfahani

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

D Lenze

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

A Koch

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

C Sers

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

F Klauschen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

I Anagnostopoulos

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Hummel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

11 September 2015

1 reference

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

page(s)

417-430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26358176%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/cgt.2015.39

2 June 2020

exact match

0 references

cites work

Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

'Basket studies' will hold intricate data for cancer drug approvals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Designing transformative clinical trials in the cancer genome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The combinatorial complexity of cancer precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

First FDA authorization for next-generation sequencer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Cancer genomics: why rare is valuable

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Detection of circulating tumor DNA in early- and late-stage human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Guideline on the requirements of external quality assessment programs in molecular pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy al

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

BRCA1 and BRCA2: different roles in a common pathway of genome protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

BRCAness: finding the Achilles heel in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Microsatellite instability in cancer of the proximal colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The minority report: targeting the rare oncogenes in NSCLC

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Novel agents in development for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Novel morphological and molecular aspects of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

"Companion diagnostics": has their time come and gone?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Melanoma epidemic: Facts and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Treating advanced melanoma: current insights and opportunities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

NRAS mutation status is an independent prognostic factor in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Switching benchmarks in cancer of unknown primary: from autopsy to microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Carcinoma of unknown primary (CUP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

A second-generation microRNA-based assay for diagnosing tumor tissue origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Hairy cell leukemia: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The variant form of hairy-cell leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Novel therapeutic options for relapsed hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Molecular pathobiology of gastrointestinal stromal sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Advances in sarcoma genomics and new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Adherence to imatinib therapy in patients with gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Advances in therapy for pediatric sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The genomic landscape of pediatric Ewing sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2015.39

Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences.

21 January 2018

1 reference

12 December 2020

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

1 reference

12 December 2020

Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis

1 reference

12 December 2020

Analysis of EPCAM protein expression in diagnostics of Lynch syndrome

1 reference

12 December 2020

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.

1 reference

12 December 2020

BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer

1 reference

12 December 2020

Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma

1 reference

12 December 2020

Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

1 reference

12 December 2020

Double-hit diffuse large B-cell lymphoma

1 reference

12 December 2020

Molecular testing and personalized treatment of lung cancer.

1 reference

12 December 2020

Molecular variant of hairy cell leukemia with poor prognosis

1 reference

12 December 2020

BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management

1 reference

12 December 2020